Welcome to our dedicated page for Revvity news (Ticker: RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity stock.
Revvity, Inc. (NYSE: RVTY) generates a steady stream of news across life sciences, diagnostics, and scientific software, reflecting its role as a global health science company and member of the S&P 500 index. Company announcements cover financial performance, strategic collaborations, product introductions, sustainability initiatives, and capital allocation decisions, offering investors and industry observers multiple angles on how Revvity operates and evolves.
On the financial side, Revvity regularly issues earnings releases and outlook updates, including preliminary expectations for quarterly results and guidance ranges for revenue and adjusted earnings per share. These updates are often accompanied by conference calls and investor presentations, which are referenced in Form 8-K filings and Business Wire releases. The company also announces actions such as share repurchase authorizations and quarterly dividends on its common stock, providing insight into capital allocation priorities.
Revvity’s news flow also highlights developments in its Signals software platform and AI-enabled discovery capabilities. Examples include the introduction of the Signals Xynthetica Models-as-a-Service offering for AI-augmented molecular and materials design, and a collaboration with Eli Lilly and Company that makes Lilly TuneLab predictive models available through the Revvity Signals platform. These stories illustrate how the company is integrating artificial intelligence, federated learning, and scientific data management to support discovery teams worldwide.
Additional news items showcase Revvity’s sustainability and ESG efforts, such as its Impact Report detailing progress on emissions, waste reduction, and social initiatives, as well as recognition through external ESG ratings and workplace certifications. Investor conference appearances and healthcare conference presentations provide further context on strategic priorities and segment performance. This news page aggregates such updates so readers can review Revvity’s financial disclosures, software and diagnostics developments, partnerships, and ESG milestones in one place.
Revvity (NYSE: RVTY) said it will release fourth-quarter and full-year 2025 results before market open on February 2, 2026 and will host a conference call at 8:00 a.m. ET. Preliminary Q4 2025 revenue is expected to be approximately $772 million with reported and organic growth of ~6% and ~4%, respectively. Full-year 2025 revenue is expected to be approximately $2,855 million with reported and organic growth of ~4% and ~3%. The company now expects full-year adjusted EPS to exceed the upper end of the prior $4.90–$5.00 guidance. The release notes use of non-GAAP measures and that adjusted EPS cannot be reconciled to GAAP without unreasonable effort.
Revvity (NYSE: RVTY) announced a collaboration with Eli Lilly to make Lilly TuneLab predictive models available through the Signals Xynthetica offering, creating a federated framework to accelerate AI-enabled drug discovery. The integration lets participating biotechs apply Lilly’s models inside the Signals platform while keeping proprietary data private via federated learning and Revvity’s Models-as-a-Service approach. Revvity’s Signals One and Signals Synergy modules provide data capture, analytics, and secure exchange to support the network. Lilly and Revvity will jointly fund access for selected participants, including software access and modeling credits, aimed at lowering barriers to AI adoption across the biotech ecosystem.
Revvity (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT. President and CEO Prahlad Singh will provide an update on the company and its strategic priorities. A live audio webcast will be available in the Events section of the company website, and a replay will be posted on the Revvity Investor Relations site and available for at least 30 days.
Revvity (NYSE: RVTY) announced Signals Xynthetica, a forthcoming AI Models-as-a-Service within the Revvity Signals platform that integrates in-silico molecular and materials design with experimental validation in a governed environment. The offering supports de novo generation, property prediction, and multi-objective optimization while enabling model governance, refreshes, and transparent evaluation alongside wet-lab results.
Revvity said pre-registration is open and early access programs begin in 1H 2026, positioning Signals Xynthetica as part of Revvity’s vision for AI-augmented discovery.
Revvity (NYSE: RVTY) entered into a definitive agreement to acquire ACD/Labs, a provider of scientific software for analytical characterization and molecular design. The transaction is expected to close late in Q4 2025. ACD/Labs products named in the announcement include Spectrus (spectral analysis), Percepta (AI molecular property and ADMET prediction), Katalyst D2D, Luminata, and ADMS.
The deal is positioned to expand Revvity Signals across discovery, development, scale-up, and manufacturing workflows and create a unified SaaS environment linking molecular design, analytical science, and quality control. Management noted customary forward-looking risks, including integration and market uncertainties.
Revvity (NYSE: RVTY) will present at three investor conferences in November–December 2025 with senior executives providing company updates and strategic priorities.
Schedule: UBS Global Healthcare Conference on Nov 10, 2025 at 8:00 a.m. ET (Max Krakowiak, SVP & CFO); Jefferies London Healthcare Conference on Nov 18, 2025 at 2:00 p.m. GMT (Max Krakowiak); and Citi Global Healthcare Conference on Dec 2, 2025 at 9:00 a.m. ET (Prahlad Singh, president & CEO).
Events are fireside chats; live audio webcasts will stream on the company Events page and replays will be posted to Revvity investor relations for at least 30 days.
Revvity (NYSE: RVTY) reported Q3 2025 results for the quarter ended September 28, 2025: revenue $699M (2% reported growth, 1% organic), GAAP EPS $0.40, and adjusted EPS $1.18. GAAP operating margin was 11.7%; adjusted operating margin was 26.1%. By segment, Life Sciences revenue was $343M (flat organic) and Diagnostics revenue was $356M (organic +2%).
The company reaffirmed 2025 organic growth guidance of 2%–4%, raised adjusted EPS guidance to $4.90–$5.00, and authorized a new $1 billion two-year share repurchase program. Management cited strategic partnerships and innovation as drivers for future execution.
Revvity (NYSE: RVTY) declared a regular quarterly dividend of $0.07 per share. The dividend is payable on February 6, 2026 to shareholders of record at the close of business on January 16, 2026.
Revvity (NYSE: RVTY) released its 2025 Impact Report, "Progress with Purpose: Science and Sustainability," summarizing sustainability, social and governance progress through 2024.
Key highlights include a 6% year-over-year reduction in Scope 1 and 2 emissions in 2024 (a 14% cumulative cut since 2022), 49% of non-hazardous waste diverted from landfills in 2024 (exceeding a 40% by-2027 target), and an AAA MSCI ESG rating. The report notes completion of a double materiality assessment and expansion of Revvity Access STEM Scholarships to global universities. The company also earned Great Place to Work recognition in multiple countries.
Revvity (NYSE: RVTY) will release its third-quarter 2025 financial results before market open on Monday, October 27, 2025. The company will hold a conference call the same day at 8:00 a.m. ET to discuss the results.
Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the call. A live audio webcast will be available in the Investors section of the company's website for access.
FAQ
What is the current stock price of Revvity (RVTY)?
What is the market cap of Revvity (RVTY)?
